TIDMCREO

RNS Number : 1927N

Creo Medical Group PLC

16 January 2019

Creo Medical Group plc

("Creo" or the "Company")

First use of Speedboat in the US

Successful patient treatments performed by two US doctors

Creo Medical Group plc (AIM: CREO), a medical device company focused on the emerging field of surgical endoscopy, announces the successful first treatment of patients in the US using its Speedboat device powered by the Company's CROMA electrosurgery advanced energy platform.

As part of the Company's strategy to establish a training-centric commercialisation programme in the US two gastrointestinal surgeons from the same hospital were trained in the use of the Speedboat device over the weekend and each performed successful operations on patients this week. The two procedures were performed in both the upper and lower gastrointestinal (GI) tract respectively.

The Company expects to increase the number of trained clinicians in the US as the roll-out of the Creo Clinical Education Programme continues and looks forward to updating shareholders on further positive progress in this key market.

Speedboat is the first device developed for use with Creo's CROMA generator, an electrosurgical platform that combines bipolar radiofrequency for precise, localised cutting and microwave for controlled coagulation. The Speedboat harnesses the cut and coagulation of the generator to enable the removal of cancerous and pre-cancerous GI growths.

Patients have now been successfully treated using the Speedboat device powered by Creo's CROMA platform in the UK, South Africa, Mainland Europe and the US.

Craig Gulliford, Creo's Chief Executive Officer, commented:

"The US is clearly a key market for the Company and the successful completion of the first procedures in the United States is another important milestone for us. Over the next few weeks and months we expect to see our Clinical Education Programme expand in the US and we will continue to update shareholders as our training-led commercialisation strategy advances."

 
 Creo Medical Group plc 
 Richard Rees (CFO)                                                    +44 (0)129 160 6005 
 
 Cenkos Securities                                                     +44 (0)20 7397 8900 
 Stephen Keys/Mark Connelly (NOMAD) 
 Michael Johnson / Russell Kerr (Sales) 
 
 Walbrook PR Ltd                           Tel: +44 (0)20 7933 8780 or creo@walbrookpr.com 
 Paul McManus                                                     Mob: +44 (0)7980 541 893 
 Helen Cresswell                                                  Mob: +44 (0)7841 917 679

This announcement contains inside information.

About Creo Medical

Creo Medical, founded in 2003, is a medical device company focused on the development and commercialisation of minimally invasive surgical devices, by bringing advanced energy to endoscopy. The Company's mission is to improve patient outcomes by applying microwave and RF energy to surgical endoscopy. Creo has developed CROMA, an electrosurgical advanced energy platform that combines bipolar radiofrequency for precise localised cutting and microwave for controlled coagulation. This technology provides clinicians with flexible, accurate and controlled surgical solutions.

The Company's strategy is to bring its CROMA platform to market through a suite of medical devices which the Company has designed, initially for the emerging field of GI therapeutic endoscopy, an area with high unmet needs. The CROMA platform will be developed further for bronchoscopy and laparoscopy procedures. The Company believes its technology can impact the landscape of surgery and endoscopy by providing a safer, less-invasive and more cost-efficient option of treatment.

For more information about Creo Medical please see our website, investors.creomedical.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

END

MSCBAMLTMBBBBBL

(END) Dow Jones Newswires

January 16, 2019 02:00 ET (07:00 GMT)

Creo Medical (LSE:CREO)
Historical Stock Chart
From Apr 2024 to May 2024 Click Here for more Creo Medical Charts.
Creo Medical (LSE:CREO)
Historical Stock Chart
From May 2023 to May 2024 Click Here for more Creo Medical Charts.